CG Oncology announces updated data on BOND-003 Cohort C

CG Oncology (CGON) announced updated data on BOND-003 Cohort C showing 12 additional patients with high risk non-muscle invasive bladder cancer, HR NMIBC, were in complete response at 24 months. The robust 24-month complete response landmark rate of 41.8% for cretostimogene monotherapy reaffirms the best-in-disease durability that the Company announced at the American Urological Association Annual Meeting in April 2025. Cretostimogene’s safety profile also remains consistent with no grade 3 or greater treatment-related adverse events or deaths reported. The Phase 3 BOND-003 Cohort C study is in patients with high-risk NMIBC unresponsive to Bacillus Calmette Guerin treatment with carcinoma in situ with or without Ta or T1 disease. The study reported 75.5% CR at any time and 41.8% at 24 months with 46 confirmed CRs as of the cutoff date of June 23, 2025. The estimated 12- and 24-month duration of response rates are 64.1% and 58.3%, respectively. Median DOR is 28 months and is ongoing. Notably, 96.6% of patients were free from progression to muscle invasive disease at 24 months.